CardioWise Software Chosen for National Heart Study

CardioWise has partnered with federal agencies to provide its cardiac analysis software for a national clinical research study, the Fayetteville startup announced Wednesday.

The beta site agreement is with the National Institutes of Health and the National Heart, Lung & Blood Institute. It will study the use of bone marrow stem cells during cardiac surgery to treat heart muscle dysfunction associated with ischemic heart disease or damage from heart attack, according to a news release.

Details of the study are available here. The study will be conducted at the NIH Heart Center at Suburban Hospital in Bethesda, Md. Suburban Hospital is a member of the Johns Hopkins Medicine system.

The software, Multiparametric Strain Analysis (MPSA), was developed to analyze the three-dimensional motion of the heart acquired from cardiac MRI images. It then compares the analysis to the motion of a normal heart model.

"The objectives of the study are to test the safety and effectiveness of bone marrow stromal stem cell injections given during heart surgery to treat heart muscle damage," said CardioWise CEO Jack Coats. "The CardioWise MPSA software will be used to help to determine the efficacy of the stem cell treatment."

Coats said the analysis detects portions of the heart that are moving abnormally and demonstrates to what degree the heart muscle has been affected.

"Since MRI uses no ionizing radiation or contrast, it is completely non-invasive and poses minimal risk to the patient," he said. "This allows the patient to be followed through the course of treatment and to measure outcomes of interventions such as the stem cell therapy. In the near future, CardioWise MPSA may aid doctors to determine what intervention, such as surgery, stent insertion or drug, is most appropriate for the patient who presents with cardiovascular disease symptoms."

CardioWise is a client firm of Innovate Arkansas and a portfolio company of VIC Technology Venture Development of Fayetteville.